Skip to content
Medical Health Aged Care, Seniors Interest

Media alert: February 26 – March 3 is Heart Valve Disease Awareness Week

hearts4heart 2 mins read

 A red and white logoDescription automatically generated with low confidence

  • Heart valve disease (HVD) affects more than half a million Australians, yet public awareness remains low. In fact, an estimated 250,000 Australians are unaware that they are living with the condition and this number is expected to grow significantly. 

  • If left untreated, HVD can damage the heart’s valves, leading to heart failure, stroke, and arrhythmia (an irregular heartbeat). 

  • Described by some researchers as 'the next cardiac epidemic', heart valve disease is on the rise due to an ageing population and under-diagnosis.
     
  • Early detection and timely treatment can increase longevity and improve quality of life for those living with HVD, making education and awareness of the disease vitally important. 

Monday, 12 February 2024, Sydney, Australia

In the lead up to Heart Valve Disease Awareness Week (February 26 – March 3), peak body hearts4heart, clinicians and people living with heart valve disease are urging Australians to have a heart-to-heart about their heart health with their GP, and for those over 65 or experiencing symptoms, to get their heart checked. 

Hearts4heart is proud to support free heart screening events during Heart Valve Disease Awareness Week at select hospitals in New South Wales and Victoria.  

The hospitals participating are: 

1. Victoria 

Hospital Name

Location

Date and Time

 

Melbourne Cardiac Services

 

 

Suite 7, 214 Burgundy Street, Heidelberg, VIC

 

 

Tuesday 27th February
(9am - 5pm AEDT)

 

 

North East Family Medicine Practice

 

 

Suite 1/90-100 Ovens Street, Wangaratta, VIC

 

 

Friday 1st March
(9am - 5pm AEDT)

 

 

2. New South Wales

Hospital Name

Location

Date and Time

 

St Vincent's Private Hospital *

 

 

406 Victoria Street, Darlinghurst, NSW

 

 

Wednesday 28th February
(8am - 2pm AEDT) 

Thursday 29th February
(10am - 4pm AEDT) 

 

 

* On Tuesday 27th February, 11am - 12:30pm AEDT, hearts4heart founder and CEO, Tanya Hall and Global Heart Hub CEO, Neil Johnson will be in attendance with a case study, clinician and local MP to speak to media about the importance of a heart check. 

 

 

Bankstown Sports Club 

 

 

8 Greenfield Parade, Bankstown, NSW 

 

 

Every day from Monday 26th February to Friday 1st March
(11am - 2pm AEDT) 

 

 

The Cardiac Centre, Bowral

 

 

3/28 Wingecarribee Street, Bowral, NSW

 

Thursday 7th March

(10am - 4pm AEDT)

 

 

 

 

-ENDS- 

Arranging interviews

We can line up interviews with a hearts4heart spokesperson, medical expert, or local case study living with the disease.   

 

Media assets  

We can assist you with a range of resources to help you build your story including content for TV, radio and online.

 

About Hearts4heart

Supported by Australian and New Zealand cardiologists, hearts4heart is a leading health promotion charity supporting, educating, and advocating for people living with heart disease. For more information visit hearts4heart.org.au 

  


Contact details:

Kerry Jung – kerry@palin.com.au 0435 753 618 

Annabel Pender - annabel@palin.com.au 0420 797 363

Media

More from this category

  • Medical Health Aged Care, Research Development
  • 17/02/2025
  • 15:07
Australia New Zealand Gynaecological Oncology Group (ANZGOG)

ANZGOG Announces Keynote Speaker for 2025 Annual Scientific Meeting: A/Professor Carien Creutzberg

The Australia New ZealandGynaecological Oncology Group (ANZGOG) is pleased to welcome internationally renowned Radiation Oncologist Professor Carien Creutzberg as a keynote speaker at the…

  • Contains:
  • Medical Health Aged Care
  • 17/02/2025
  • 11:51
Monash University

Monash Expert: Landmark approval of weight loss drug for heart disease

For the first time in Australia, a weight loss drug has been approved to also treat cardiovascular disease in overweight and obese patients. The Therapeutic Goods Administration (TGA) has granted approval for semaglutide 2.4 mg (sold as Wegovy) to be used as a complementary therapy for reducing major adverse cardiovascular events such as cardiovascular death, non-fatal myocardial infarction (heart attack), or non-fatal stroke. The approval follows findings from the SELECT trial, an international study involving more than 17,000 participants across 41 countries, including Australia. Results published in late 2023 showed that Wegovy reduced cardiovascular events by 20 percent in people…

  • Medical Health Aged Care
  • 17/02/2025
  • 10:11
Smith & Nephew UK Ltd

Smith+Nephew steps forward with innovative Sports Medicine foot & ankle repair solutions in Australia and New Zealand

First in market to offer Adjustable Tensioning Technology* for insertional Achilles reconstruction and lateral ankle instability repair*After anchor insertionSmith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of a comprehensive foot & ankle repair portfolio in Australia and New Zealand (ANZ) with proprietary adjustable tensioning technology. The ULTRABRIDGE◊ Adjustable Achilles Reconstruction and ULTRABRACE◊ Adjustable Ankle Instability Techniques are changing the way foot & ankle surgeons perform these repairs by allowing them to refine and optimise suture tension after anchor insertion.The ability to adjust tension for specific patients allows the surgeon to give the precise amount of range-of-motion…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.